For FY23, AstraZeneca said total revenue is expected to increase by a low-to-mid single-digit percentage, total revenue excluding COVID-19 medicines is expected to increase by a low double-digit percentage and core EPS is expected to increase by a high single-digit to low double-digit percentage.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca Gains after Q4 Results Beat Estimates
- AstraZeneca’s Forxiga approved in E.U. for treatment of chronic heart failure
- Amgen’s Tezspire approved in U.S. for self-administration in severe asthma
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- AstraZeneca continuing to work with FDA to collect data on Evusheld and variants
